Package | us.nlm.vsac |
Resource Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1196.495 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1196.495/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495 |
Version | 20210909 |
Status | active |
Date | 2021-09-09T01:01:05-04:00 |
Name | ICSLABALAMAPreparations |
Title | ICS LABA LAMA Preparations |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: This valueset contains oral inhaled corticosteroid preparations in combination with a long-acting beta agonist and a long-acting muscarinic antagonist that may be used for maintenance controller therapy in adult asthmatics. As of Sept 2020, the oral inhalant combination of fluticasone furoate + umeclidinium + vilanterol is indicated for the maintenance treatment of asthma in patients aged 18 years and older.),(Data Element Scope: FHIR MedicationStatement.medicationCodeableConcept, MedicationRequest.medicationCodeableConcept),(Inclusion Criteria: Includes fluticasone/umeclidinium/vilanterol oral inhalation preparations),(Exclusion Criteria: none) |
No resources found
CodeSystem | |
rxnorm | RxNorm |
No narrative content found in resource
{ "resourceType": "ValueSet", "id": "2.16.840.1.113762.1.4.1196.495", "meta": { "versionId": "16", "lastUpdated": "2023-12-21T17:43:03.000-05:00", "profile": [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ] }, "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/valueset-author", "valueContactDetail": { "name": "Elimu Informatics Author" } }, { "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate", "valueDate": "2025-03-03" }, { "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate", "valueDate": "2021-09-09" } ], "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495", "identifier": [ { "system": "urn:ietf:rfc:3986", "value": "urn:oid:2.16.840.1.113762.1.4.1196.495" } ], "version": "20210909", "name": "ICSLABALAMAPreparations", "title": "ICS LABA LAMA Preparations", "status": "active", "experimental": false, "date": "2021-09-09T01:01:05-04:00", "publisher": "NHLBI Implementation Science and Health Care Innovation Steward", "jurisdiction": [ { "coding": [ { "system": "urn:iso:std:iso:3166", "code": "US" } ] } ], "purpose": "(Clinical Focus: This valueset contains oral inhaled corticosteroid preparations in combination with a long-acting beta agonist and a long-acting muscarinic antagonist that may be used for maintenance controller therapy in adult asthmatics. As of Sept 2020, the oral inhalant combination of fluticasone furoate + umeclidinium + vilanterol is indicated for the maintenance treatment of asthma in patients aged 18 years and older.),(Data Element Scope: FHIR \nMedicationStatement.medicationCodeableConcept, MedicationRequest.medicationCodeableConcept),(Inclusion Criteria: Includes fluticasone/umeclidinium/vilanterol oral inhalation preparations),(Exclusion Criteria: none)", "compose": { "include": [ { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "concept": [ { "code": "1945039", "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler" }, { "code": "1945044", "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]" }, { "code": "1945047", "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler" }, { "code": "1945048", "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]" } ] } ] }, "expansion": { "identifier": "urn:uuid:c37db04e-d713-4f93-b185-7c9489baf734", "timestamp": "2025-05-23T19:13:52-04:00", "total": 4, "contains": [ { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "version": "05052025", "code": "1945039", "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler" }, { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "version": "05052025", "code": "1945044", "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]" }, { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "version": "05052025", "code": "1945047", "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler" }, { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "version": "05052025", "code": "1945048", "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]" } ] } }